13th Conference on Retroviruses and Opportunistic Infections


Denver, Colorado - February 5-8, 2006



THE PRICE OF ANTIRETROVIRAL THERAPY IN CHILDREN: FOCUS ON METABOLIC MORBIDITIES

Conf Retrovir Opportunistic Infect 2006 Feb 5-8;13:abstract no. 24

Grace McComsey
Rainbow Babies and Children's Hosp and Case Western Reserve Univ, Cleveland, OH, US


BACKGROUND: The virological and immunological successes of ART certainly promise a longer life-span for HIV-infected children, but the long-term metabolic consequences of this therapy are of serious concern. Not enough data exist about the long-term consequences of these metabolic derangements in children receiving ART; however, the likely long-term exposure to these drugs makes these derangements a serious concern. Among all of prolonged ART’s complications, body fat changes, dyslipidemia, insulin resistance, and osteopenia are the most concerning. The adult medical literature contains numerous studies related to these complications; however, the pediatric literature remains relatively sparse.

CONCLUSIONS: This overview summarizes the epidemiology, clinical presentation, and management of lipodystrophy, dyslipidemia, insulin resistance, hyperlactatemia, and decreased bone mineral density in HIV-infected children. In addition to describing the available pediatric data, this presentation will summarize and put in perspective for pediatricians the reported data on these complications from studies of HIV-infected adults.

Acrobat ReaderDownload abstract

2006-02-05
24

Copyright © 2006 - Foundation for Retrovirology and Human Health. Reproduction of this abstract (other than one copy for personal reference) must be cleared through the Foundation for Retrovirology and Human Health.